Crixivan (indinavir)
- Region
- 🇪🇺 EU
- Active substance
- indinavir
- Company
- Merck Sharp & Dohme B.V.
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- EU approval
- Fri 04 Oct 1996
- Application
- EMEA/H/C/000128
- ATC
- J05AE02
- Official record
- www.ema.europa.eu
Indication
Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.
Regulatory milestones
No milestones recorded in the last year.
Follow Crixivan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.